Takeda Pharmaceutical Co ADR (NYSE: TAK) kicked off on Tuesday, down -0.60% from the previous trading day, before settling in for the closing price of $14.89. Over the past 52 weeks, TAK has traded in a range of $12.57-$16.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 11.56% over the past five years. While this was happening, its average annual earnings per share was recorded -23.52%. With a float of $3.15 billion, this company’s outstanding shares have now reached $3.16 billion.
Let’s look at the performance matrix of the company that is accounted for 49281 employees.
Takeda Pharmaceutical Co ADR (TAK) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Takeda Pharmaceutical Co ADR is 0.02%, while institutional ownership is 5.06%. The most recent insider transaction that took place on Aug 23 ’24, was worth 284,951. Before that another transaction happened on Jan 24 ’24, when Company’s 10% Owner sold 3,703,703 for $8.10, making the entire transaction worth $29,999,994. This insider now owns 3,755,583 shares in total.
Takeda Pharmaceutical Co ADR (TAK) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -23.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.02% during the next five years compared to -12.87% drop over the previous five years of trading.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
Take a look at Takeda Pharmaceutical Co ADR’s (TAK) current performance indicators. Last quarter, stock had a quick ratio of 0.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.58. Likewise, its price to free cash flow for the trailing twelve months is 12.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.31, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.46 in one year’s time.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
Takeda Pharmaceutical Co ADR (NYSE: TAK) saw its 5-day average volume 1.63 million, a negative change from its year-to-date volume of 1.86 million. As of the previous 9 days, the stock’s Stochastic %D was 59.65%. Additionally, its Average True Range was 0.17.
During the past 100 days, Takeda Pharmaceutical Co ADR’s (TAK) raw stochastic average was set at 88.82%, which indicates a significant increase from 42.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 8.86% in the past 14 days, which was lower than the 18.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.35, while its 200-day Moving Average is $13.98. Nevertheless, the first resistance level for the watch stands at $14.86 in the near term. At $14.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.98. If the price goes on to break the first support level at $14.74, it is likely to go to the next support level at $14.67. The third support level lies at $14.62 if the price breaches the second support level.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Key Stats
The company with the Market Capitalisation of 46.70 billion has total of 3,164,837K Shares Outstanding. Its annual sales at the moment are 29,420 M in contrast with the sum of 994,060 K annual income. Company’s last quarter sales were recorded 7,731 M and last quarter income was 609,590 K.
